Similar articles

• A novel therapeutic approach to the treatment of scleroderma-associated pulmonary complications: safety and efficacy of combination therapy with imatinib and cyclophosphamide.

  Sabnani I, Zucker MJ, Rosenstein ED, Baran DA, Arroyo LH, Tsang P, Zubair M, Rivera V. Sabnani I, et al. Rheumatology (Oxford). 2009 Jan;48(1):49-52. doi: 10.1093/rheumatology/ken369. Epub 2008 Sep 24. Rheumatology (Oxford). 2009. PMID: 18815156 Clinical Trial.
• A one-year, phase I/IIa, open-label pilot trial of imatinib mesylate in the treatment of systemic sclerosis-associated active interstitial lung disease.

  Khanna D, Saggar R, Mayes MD, Abtin F, Clements PJ, Maranian P, Assassi S, Saggar R, Singh RR, Furst DE. Khanna D, et al. Arthritis Rheum. 2011 Nov;63(11):3540-6. doi: 10.1002/art.30548. Arthritis Rheum. 2011. PMID: 21769849 Free PMC article. Clinical Trial.
• Imatinib mesylate (Gleevec™) in the treatment of diffuse cutaneous systemic sclerosis: results of a 24-month open label, extension phase, single-centre trial.

  Gordon J, Udeh U, Doobay K, Magro C, Wildman H, Davids M, Mersten JN, Huang WT, Lyman S, Crow MK, Spiera RF. Gordon J, et al. Clin Exp Rheumatol. 2014 Nov-Dec;32(6 Suppl 86):S-189-93. Epub 2014 Aug 15. Clin Exp Rheumatol. 2014. PMID: 25152211 Clinical Trial.
• Imatinib and the treatment of fibrosis: recent trials and tribulations.

  Gordon J, Spiera R. Gordon J, et al. Curr Rheumatol Rep. 2011 Feb;13(1):51-8. doi: 10.1007/s11926-010-0146-6. Curr Rheumatol Rep. 2011. PMID: 21086081 Review.
• Current concepts in disease-modifying therapy for systemic sclerosis-associated interstitial lung disease: lessons from clinical trials.

  Au K, Khanna D, Clements PJ, Furst DE, Tashkin DP. Au K, et al. Curr Rheumatol Rep. 2009 Apr;11(2):111-9. doi: 10.1007/s11926-009-0016-2. Curr Rheumatol Rep. 2009. PMID: 19296883 Review.